Literature DB >> 12095254

The nuclease A inhibitor represents a new variation of the rare PR-1 fold.

Thomas W Kirby1, Geoffrey A Mueller, Eugene F DeRose, Mark S Lebetkin, Gregor Meiss, Alfred Pingoud, Robert E London.   

Abstract

Nuclease A (NucA) from Anabaena sp. is a non-specific endonuclease able to degrade single and double-stranded DNA and RNA. The endonucleolytic activity is inhibited by the nuclease A inhibitor (NuiA), which binds to NucA with 1:1 stoichiometry and picomolar affinity. In order to better understand the mechanism of inhibition, the solution structure of NuiA was determined by NMR methods. The fold of NuiA is an alpha-beta-alpha sandwich but standard database searches by DALI and TOP revealed no structural homologies. A visual inspection of alpha-beta-alpha folds in the CATH database revealed similarities to the PR-1-like fold (SCOP nomenclature). The similarities include the ordering of secondary structural elements, a single helix on one face of the alpha-beta-alpha sandwich, and three helices on the other face. However, a major difference is in the IV helix, which in the PR-1 fold is short and perpendicular to the I and III helices, but in NuiA is long and parallel to the I and III helices. Additionally, a strand insertion in the beta-sheet makes the NuiA beta-sheet completely antiparallel in organization. The fast time-scale motions of NuiA, characterized by enhanced flexibility of the extended loop between helices III and IV, also show similarities to P14a, which is a PR-1 fold. We propose that the purpose of the PR-1 fold is to form a stable scaffold to present this extended structure for biological interactions with other proteins. This hypothesis is supported by data that show that when NuiA is bound to NucA significant changes in chemical shift occur in the extended loop between helices III and IV. (c) 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095254     DOI: 10.1016/s0022-2836(02)00460-6

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Molecular characterization and genomic mapping of the pathogenesis-related protein 1 (PR-1) gene family in hexaploid wheat (Triticum aestivum L.).

Authors:  Shunwen Lu; Timothy L Friesen; Justin D Faris
Journal:  Mol Genet Genomics       Date:  2011-04-23       Impact factor: 3.291

2.  The nuclease a-inhibitor complex is characterized by a novel metal ion bridge.

Authors:  Mahua Ghosh; Gregor Meiss; Alfred M Pingoud; Robert E London; Lars C Pedersen
Journal:  J Biol Chem       Date:  2006-11-30       Impact factor: 5.157

3.  Analytical solution to the coupled evolution of multidimensional NMR data.

Authors:  Geoffrey A Mueller
Journal:  J Biomol NMR       Date:  2009-03-24       Impact factor: 2.835

4.  Mechanism by which T7 bacteriophage protein Gp1.2 inhibits Escherichia coli dGTPase.

Authors:  Bradley P Klemm; Deepa Singh; Cassandra E Smith; Allen L Hsu; Lucas B Dillard; Juno M Krahn; Robert E London; Geoffrey A Mueller; Mario J Borgnia; Roel M Schaaper
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-06       Impact factor: 12.779

5.  TaPR1 Interacts With TaTLP1 via the αIV Helix to Be Involved in Wheat Defense to Puccinia triticina Through the CAPE1 Motif.

Authors:  Fei Wang; Songsong Shen; Cunpeng Zhao; Zhongchi Cui; Linshuo Meng; Wenyue Wu; Daqun Liu; Haiyan Wang
Journal:  Front Plant Sci       Date:  2022-05-26       Impact factor: 6.627

6.  The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.

Authors:  Vineet Choudhary; Rabih Darwiche; David Gfeller; Vincent Zoete; Olivier Michielin; Roger Schneiter
Journal:  J Lipid Res       Date:  2014-03-05       Impact factor: 5.922

7.  Crystal structure of the EndoG/EndoGI complex: mechanism of EndoG inhibition.

Authors:  Bernhard Loll; Maike Gebhardt; Elmar Wahle; Anton Meinhart
Journal:  Nucleic Acids Res       Date:  2009-11       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.